NEW ORLEANS, June 17, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, described today at the 55th annual meeting of the Society of Nuclear Medicine a novel method for attaching fluorine-18 (F-18) to peptides, which in pretargeting studies using a human colorectal cancer model, produced exceptional positron emission tomography (PET) images.
